The Use of Biologics for the Treatment of Asthma

This Peer Exchange based panel discussion reviewed the use of biologics for the treatment of asthma. The panel discussed the available biomarkers and biologic agents for asthma. They discussed the patient factors used to determine the need for biologics.

Tap into peer-to-peer dialogues covering different therapeutic areas in easy to digest videos, featuring managed care thought leaders.

Experience With Biologics and Pathways
March 01, 2019 – 
Panelists share their personal experiences with biologics and the benefit of pathways.
Severe Patients and Final Thoughts
March 01, 2019 – 
Experts provide final thoughts on treatment and asthma.

 
IL-5–Inhibiting Agents Mepolizumab, Benralizumab, and Reslizumab
February 22, 2019 – 
Experts review the IL-5–inhibiting agents mepolizumab, benralizumab, and reslizumab.
 
Dupilumab: Mechanism, Dosing, and Pivotal Trials
February 22, 2019 – 
Experts provide an overview of dupilumab, including mechanism of action, dosing, and pivotal trials.
 
Uncontrolled Severe Asthma and Difference among Biologics
February 15, 2019 – 
Define unmanaged/uncontrolled severe asthma and provide an overview of the available biologics.
Omalizumab: Adverse effects, Mechanism, and Patient Factors
February 15, 2019 – 
A review of Omalizumab’s adverse effects, mechanism, and ideal patient factors.
 
Biomarkers–Diagnostic Tool for Optimal Therapy
February 08, 2019 – 
A discussion on the biomarkers used to determine efficacy with specific biologics.
 
Challenges of Biologics in the Treatment Plan
February 08, 2019 – 
Experts debate the challenges with biologics in the treatment plan for severe asthma.
Recommended Guidelines and Restrictions in Asthma
February 01, 2019 – 
Defining the recommended guidelines and the formulary restrictions with the standard of care for asthma.
 
Targeted Pathology and Associated Biomarkers in Asthma
February 01, 2019 – 
A review of the targeted pathway for the treatment of asthma and the associated biomarkers.
 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.